Avaí Bio and Austrianova have outlined preclinical progress on Klothonova, an encapsulated-cell therapy candidate targeting ageing. The joint venture presented GMP cell-bank data at a Miami longevity conference.
Avaí Bio and Austrianova present Klothonova encapsulated-cell data
The preclinical joint venture presented its α-Klotho cell-encapsulation programme at a Miami longevity conference, outlining progress on a GMP cell bank.
biotech.disruptsmedia.com
September 29, 2026 at 2:46 PM
Avaí Bio and Austrianova have outlined preclinical progress on Klothonova, an encapsulated-cell therapy candidate targeting ageing. The joint venture presented GMP cell-bank data at a Miami longevity conference.
@bdelloid.bsky.social part 2 is now live! Might be a good real world example of how you can take preclinical data into humans and slowly tease the confounders apart to arrive at an answer. Science! Slow, iterative and yet satisfying!
September 29, 2026 at 1:50 PM
@bdelloid.bsky.social part 2 is now live! Might be a good real world example of how you can take preclinical data into humans and slowly tease the confounders apart to arrive at an answer. Science! Slow, iterative and yet satisfying!
🧠 New paper from the Audimotor Disorders & Reflex Epilepsies Laboratory (TAM)!
Can biological sex influence CBD’s effects on epilepsy? Our study in Frontiers in Pharmacology reveals sex-related molecular differences in the epileptic brain.
🔗 doi.org/10.3389/fpha...
Can biological sex influence CBD’s effects on epilepsy? Our study in Frontiers in Pharmacology reveals sex-related molecular differences in the epileptic brain.
🔗 doi.org/10.3389/fpha...
Frontiers | Anticonvulsant effects, safety, and sex-dependent molecular signatures of cannabidiol treatment in a preclinical model of audiogenic epilepsy
Roughly one-third of patients with epilepsy remain drug resistant, underscoring the need for novel therapeutic strategies. Although cannabidiol (CBD) has rec...
doi.org
September 29, 2026 at 1:29 PM
🧠 New paper from the Audimotor Disorders & Reflex Epilepsies Laboratory (TAM)!
Can biological sex influence CBD’s effects on epilepsy? Our study in Frontiers in Pharmacology reveals sex-related molecular differences in the epileptic brain.
🔗 doi.org/10.3389/fpha...
Can biological sex influence CBD’s effects on epilepsy? Our study in Frontiers in Pharmacology reveals sex-related molecular differences in the epileptic brain.
🔗 doi.org/10.3389/fpha...
Kyle Valentino discusses the comorbid theory of aggression and how various psychological pathologies are linked to and overlap with aggressive behaviour.
Watch the full seminar here: www.youtube.com/watch?v=52Uf...
#Neuroscience #MentalHealthResearch
Watch the full seminar here: www.youtube.com/watch?v=52Uf...
#Neuroscience #MentalHealthResearch
The Neural Control of Aggressive Behavior - Preclinical, Clinical and Evolutionary Data
YouTube video by Valentino Group
www.youtube.com
September 29, 2026 at 12:35 PM
Kyle Valentino discusses the comorbid theory of aggression and how various psychological pathologies are linked to and overlap with aggressive behaviour.
Watch the full seminar here: www.youtube.com/watch?v=52Uf...
#Neuroscience #MentalHealthResearch
Watch the full seminar here: www.youtube.com/watch?v=52Uf...
#Neuroscience #MentalHealthResearch
🚨 $NAMSW
On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.
On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.
SEC Filing: NAMSW
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 12:23 PM
🚨 $NAMSW
On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.
On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.
Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program#United_States#Cambridge#COVID-19#Decoy_Therapeutics#DCOY-CoV
Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program
Decoy Therapeutics has shared groundbreaking preclinical data suggesting a weekly intranasal dosing regimen for its DCOY-CoV initiative, maintaining drug efficacy for up to a week.
third-news.com
September 29, 2026 at 11:40 AM
Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program#United_States#Cambridge#COVID-19#Decoy_Therapeutics#DCOY-CoV
#DCOY Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
https://www.stocktitan.net/news/DCOY/decoy-therapeutics-reports-preclinical-data-supporting-once-weekly-r1974ejubbj5.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DCOY/decoy-therapeutics-reports-preclinical-data-supporting-once-weekly-r1974ejubbj5.html?utm_source=stocktitan-bluesky&utm_medium=social
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 29, 2026 at 11:30 AM
#DCOY Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
https://www.stocktitan.net/news/DCOY/decoy-therapeutics-reports-preclinical-data-supporting-once-weekly-r1974ejubbj5.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/DCOY/decoy-therapeutics-reports-preclinical-data-supporting-once-weekly-r1974ejubbj5.html?utm_source=stocktitan-bluesky&utm_medium=social
Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240 #NeuroDegeneration 🧪🧠
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71861?af=R
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71861?af=R
September 29, 2026 at 10:04 AM
Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240 #NeuroDegeneration 🧪🧠
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71861?af=R
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71861?af=R
Signal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from
in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical
in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from
in-demand Hengrui
Novo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
dlvr.it
September 29, 2026 at 9:57 AM
Signal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from
in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical
in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical
Other experiments concern the investigation of which preclinical model is best for testing vaccines for humans. That has also been done. No, not something scary, but something that benefits us all and is conducted under strict BLS-4 conditions.
www.sciencedirect.co...
8/8
www.sciencedirect.co...
8/8
Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology
There is little known concerning the disease caused by Zaire ebolavirus (ZEBOV) when inhaled, the likely route of exposure in a biological attack. Cyn…
www.sciencedirect.com
September 29, 2026 at 9:50 AM
Other experiments concern the investigation of which preclinical model is best for testing vaccines for humans. That has also been done. No, not something scary, but something that benefits us all and is conducted under strict BLS-4 conditions.
www.sciencedirect.co...
8/8
www.sciencedirect.co...
8/8
When Amgen Tried to Replicate Cancer Research and Failed 89 Percent of the Time
https://mixcache.com/blog/post/when-amgen-tried-to-replicate-cancer-research-and-failed-89-percent-of-the-time-story-12968
https://mixcache.com/blog/post/when-amgen-tried-to-replicate-cancer-research-and-failed-89-percent-of-the-time-story-12968
When Amgen Tried to Replicate Cancer Research and Failed 89 Percent of the Time - MixCache.com Blog
A quiet project inside a major pharmaceutical company exposed a crisis in preclinical science that still reshapes how drugs are developed today.
mixcache.com
September 29, 2026 at 9:13 AM
When Amgen Tried to Replicate Cancer Research and Failed 89 Percent of the Time
https://mixcache.com/blog/post/when-amgen-tried-to-replicate-cancer-research-and-failed-89-percent-of-the-time-story-12968
https://mixcache.com/blog/post/when-amgen-tried-to-replicate-cancer-research-and-failed-89-percent-of-the-time-story-12968
#MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
pharmaphorum.com/news/msd-tak...
pharmaphorum.com/news/msd-tak...
MSD takes a $400m bite of SciBrunch's KRAS drug
MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
pharmaphorum.com
September 29, 2026 at 9:07 AM
#MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
pharmaphorum.com/news/msd-tak...
pharmaphorum.com/news/msd-tak...
✨ EvaMobs was back at European Researchers’ Night! Visitors explored antiviral drug discovery hands-on: targeting viruses, identifying promising proteins computationally, and progressing through production and preclinical testing toward a clinical candidate. 🔬🧪 evamobs.eu
@itqbnova.bsky.social
@itqbnova.bsky.social
September 29, 2026 at 8:33 AM
✨ EvaMobs was back at European Researchers’ Night! Visitors explored antiviral drug discovery hands-on: targeting viruses, identifying promising proteins computationally, and progressing through production and preclinical testing toward a clinical candidate. 🔬🧪 evamobs.eu
@itqbnova.bsky.social
@itqbnova.bsky.social
....In nextgen Covid vaccines news, there are:
—results from a phase 2 trial of a "variant-proof" vaccine
—a phase 1/2 clinical trial of a featured vax has fully recruited
— 10 preclinical reports
vaxtracker.wordpress.com/2026/09/29/t...
—results from a phase 2 trial of a "variant-proof" vaccine
—a phase 1/2 clinical trial of a featured vax has fully recruited
— 10 preclinical reports
vaxtracker.wordpress.com/2026/09/29/t...
Flu-Covid combo vax & monthly update of nextgen Covid vax news
Moderna has the first combined flu-Covid vaccine to cross the finish line. An overview of that race plus an update on nextgen Covid vaccine news.
vaxtracker.wordpress.com
September 29, 2026 at 6:19 AM
....In nextgen Covid vaccines news, there are:
—results from a phase 2 trial of a "variant-proof" vaccine
—a phase 1/2 clinical trial of a featured vax has fully recruited
— 10 preclinical reports
vaxtracker.wordpress.com/2026/09/29/t...
—results from a phase 2 trial of a "variant-proof" vaccine
—a phase 1/2 clinical trial of a featured vax has fully recruited
— 10 preclinical reports
vaxtracker.wordpress.com/2026/09/29/t...
The >1,000:1 figure compares drug exposure in gut tissue with exposure in blood. In preclinical studies, KQTD-126 also inhibited TRKA, TRKB, and TRKC at IC₅₀ <1 nM and showed high selectivity over other kinases.
September 29, 2026 at 2:52 AM
The >1,000:1 figure compares drug exposure in gut tissue with exposure in blood. In preclinical studies, KQTD-126 also inhibited TRKA, TRKB, and TRKC at IC₅₀ <1 nM and showed high selectivity over other kinases.
🐭 Tauopathy may involve more than tau. In mice, blocking CXCR3 reduced brain-infiltrating T cells, neurodegeneration and some memory deficits—without lowering bulk tau. Intriguing immune-targeting result, but still preclinical. www.cell.com/neuron/fullt... #Neuroscience #neuroskyence #photography
Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy
Emmerson et al. demonstrate that the CXCR3-CXCL10 chemokine signaling pathway is important
for brain-infiltrating T cells in tau-mediated neurodegeneration. Blocking CXCR3 reduces
T cell entry and pro...
www.cell.com
September 29, 2026 at 1:46 AM
🐭 Tauopathy may involve more than tau. In mice, blocking CXCR3 reduced brain-infiltrating T cells, neurodegeneration and some memory deficits—without lowering bulk tau. Intriguing immune-targeting result, but still preclinical. www.cell.com/neuron/fullt... #Neuroscience #neuroskyence #photography
🧠🔬Could a GLP-1 receptor agonist modulate key pathways in temporal lobe epilepsy? This study explores how liraglutide influences inflammation, oxidative stress, mitochondrial function, and behavior in a preclinical TLE model. #Epilepsy #Liraglutide
www.mdpi.com/2227-9059/12...
www.mdpi.com/2227-9059/12...
September 29, 2026 at 12:56 AM
🧠🔬Could a GLP-1 receptor agonist modulate key pathways in temporal lobe epilepsy? This study explores how liraglutide influences inflammation, oxidative stress, mitochondrial function, and behavior in a preclinical TLE model. #Epilepsy #Liraglutide
www.mdpi.com/2227-9059/12...
www.mdpi.com/2227-9059/12...
New in peptide research: "BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence" (International journal of molecular sciences)
https://pubmed.ncbi.nlm.nih.gov/42794771/
#peptides #research
https://pubmed.ncbi.nlm.nih.gov/42794771/
#peptides #research
September 28, 2026 at 11:00 PM
New in peptide research: "BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence" (International journal of molecular sciences)
https://pubmed.ncbi.nlm.nih.gov/42794771/
#peptides #research
https://pubmed.ncbi.nlm.nih.gov/42794771/
#peptides #research
An experimental mRNA therapy reduced liver injury in mice six hours after acetaminophen overdose. In mice, the current antidote offered no protection beyond two hours.
Experimental mRNA therapy dramatically extends treatment window for acetaminophen overdose in preclinical models
When a patient arrives at the hospital with an acetaminophen overdose, it's often a race against the clock. The only FDA-approved antidote for overdose-related liver injury, N‑acetylcysteine, must be administered within hours to be effective.
medicalxpress.com
September 28, 2026 at 7:01 PM
An experimental mRNA therapy reduced liver injury in mice six hours after acetaminophen overdose. In mice, the current antidote offered no protection beyond two hours.
In a new video, @ucsfimaging.bsky.social's Dr. Pavithra Viswanath shows how a specialized scan can reveal whether a therapy is working against a fast-growing childhood brain tumor, work still in preclinical research.
Watch now: www.youtube.com/watch?v=qTye... #WIMM #WomenInMedicineMonth
Watch now: www.youtube.com/watch?v=qTye... #WIMM #WomenInMedicineMonth
Monitoring Diffuse Midline Glioma: Pavithra Viswanath, PhD
Pavithra Viswanath, PhD, imaging scientist at UCSF, conducts pre-clinical trials using a new application of deuterium metabolic imaging (DMI) to monitor how pediatric diffuse midline glioma grows and…
www.youtube.com
September 28, 2026 at 6:12 PM
In a new video, @ucsfimaging.bsky.social's Dr. Pavithra Viswanath shows how a specialized scan can reveal whether a therapy is working against a fast-growing childhood brain tumor, work still in preclinical research.
Watch now: www.youtube.com/watch?v=qTye... #WIMM #WomenInMedicineMonth
Watch now: www.youtube.com/watch?v=qTye... #WIMM #WomenInMedicineMonth
Oncolytics: REO 033 sites activated, interim update targeted by year-end
www.merlintrader.com/oncolytics-b...
www.merlintrader.com/oncolytics-b...
Oncolytics Biotech ($ONCY): FDA Alignment On Pelareorep Path
Oncolytics Biotech ($ONCY): FDA feedback on a pivotal REO 033 Part B for pelareorep, pan-RAS preclinical data, $4.12M of cash and the Nasdaq timeline.
www.merlintrader.com
September 28, 2026 at 5:33 PM
Oncolytics: REO 033 sites activated, interim update targeted by year-end
www.merlintrader.com/oncolytics-b...
www.merlintrader.com/oncolytics-b...
Annamycin cardiac safety now peer-reviewed
www.merlintrader.com/moleculin-bi...
www.merlintrader.com/moleculin-bi...
Moleculin ($MBRX): Preclinical Pancreatic Cancer Data
Moleculin $MBRX: AACR pancreatic cancer findings are preclinical, not a clinical pancreas program or new MIRACLE AML efficacy readout.
www.merlintrader.com
September 28, 2026 at 4:44 PM
Annamycin cardiac safety now peer-reviewed
www.merlintrader.com/moleculin-bi...
www.merlintrader.com/moleculin-bi...
A new lipid nanoparticle, LC-1, overcame gene editing barriers and efficiently delivered large RNA tools to the preclinical models of liver, lungs, and brain.
The Nature Biotechnology study was led by Dr. Bowen Li @uhn.ca Princess Margaret Cancer Centre:
www.nature.com/articles/s41...
The Nature Biotechnology study was led by Dr. Bowen Li @uhn.ca Princess Margaret Cancer Centre:
www.nature.com/articles/s41...
September 28, 2026 at 3:29 PM
A new lipid nanoparticle, LC-1, overcame gene editing barriers and efficiently delivered large RNA tools to the preclinical models of liver, lungs, and brain.
The Nature Biotechnology study was led by Dr. Bowen Li @uhn.ca Princess Margaret Cancer Centre:
www.nature.com/articles/s41...
The Nature Biotechnology study was led by Dr. Bowen Li @uhn.ca Princess Margaret Cancer Centre:
www.nature.com/articles/s41...
A reconfigurable helical brace can stabilize a telerobotic catheter or endoscope without obstructing blood flow, enabling telerobotic needle interventions such as drug delivery and fluid aspiration within the lungs in preclinical models.
Learn more in #ScienceRobotics: https://scim.ag/4dMK2ow
Learn more in #ScienceRobotics: https://scim.ag/4dMK2ow
September 28, 2026 at 3:25 PM
A reconfigurable helical brace can stabilize a telerobotic catheter or endoscope without obstructing blood flow, enabling telerobotic needle interventions such as drug delivery and fluid aspiration within the lungs in preclinical models.
Learn more in #ScienceRobotics: https://scim.ag/4dMK2ow
Learn more in #ScienceRobotics: https://scim.ag/4dMK2ow
Could a bee-venom peptide become a targeted cancer drug? Scientists are studying ways to deliver melittin to tumors while limiting damage to healthy cells. Promising but still largely preclinical. #CancerResearch #Melittin #BeeVenom #Medicine #ScienceExplained
September 28, 2026 at 3:11 PM
Could a bee-venom peptide become a targeted cancer drug? Scientists are studying ways to deliver melittin to tumors while limiting damage to healthy cells. Promising but still largely preclinical. #CancerResearch #Melittin #BeeVenom #Medicine #ScienceExplained